Status: Baseline only

  
Image
Baseline

Increase the proportion of adults with diagnosed diabetes and chronic kidney disease who receive recommended medical treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)

Baseline: 43.0 percent of adults aged 18 years and over with diagnosed diabetes and chronic kidney disease received recommended medical treatment with ACE inhibitors or ARBs in 2013-16 (age adjusted to the year 2000 standard population)

Target: 55.4 percent

Target Setting Method
Minimal statistical significance

Summary

High blood pressure and diabetes are the leading causes of end-stage kidney disease. And when people with chronic kidney disease (CKD) have untreated high blood pressure, it can lead to heart attack, stroke, heart failure, and early death. Research has shown that ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin II receptor blockers), both medications that treat high blood pressure, can reduce kidney damage in diabetes patients with CKD.